Oxford, UK – 28 August 2014: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), a world-leading gene and cell therapy company, today announces its unaudited interim results for the…
— Dr Paul Blake to take Executive Role as Chief Development Officer — Oxford, UK – 15 August 2014: Oxford BioMedica plc (LSE: OXB), (“OXB” or “the Company”) a leading gene…
Oxford, UK – 23 June 2014: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company, today announces that it will attend Piper Jaffray’s GenomeRx Symposium…
Oxford, UK – 18 June 2014: Oxford BioMedica (“the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company, announces that the Company has repaid in full the amount drawn down from the…
Oxford, UK – 03 June 2014: Oxford BioMedica (“the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company, announced today that all resolutions proposed were duly passed at its Annual General…
Oxford, UK – 13 May 2014: Oxford BioMedica plc (LSE: OXB), (“the Company”) the leading gene based biopharmaceutical company, today publishes its interim management statement for the period 1 January…
£2.2M award will be used to fund a Phase I/II clinical trial of OXB-102, an enhanced version of ProSavin®; a gene therapy for the treatment of Parkinson’s disease Oxford, UK –…
Oxford, UK – 29 April 2014: Oxford BioMedica plc (LSE: OXB), (“the Company”) the leading gene based biopharmaceutical company, announces that it will regain the worldwide rights to RetinoStat®, a treatment for…
Click here to download the full 2013 Preliminary Results Statement.Click here to download the 2013 Results Presentation.Click here to listen to the 2013 Results Audio Replay file. Oxford, UK – 10…
— Planned 21 patients dosed in “wet” age-related macular degeneration (wet AMD) US Phase I trial Oxford, UK – 7 April 2014: Oxford BioMedica plc (LSE: OXB), (“the Company”) the…
Oxford, UK – 21 March 2014: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company, announces that John Dawson, Chief Executive Officer, will present…
— Oxford BioMedica regains worldwide rights to EncorStat® — — Sanofi broadens global rights to StarGen™ and UshStat® across all disease indications – — EncorStat® Phase I/IIa study funded from previously announced…